journal article·2017-09

Drug‐Loaded Multifunctional Nanoparticles Targeted to the Endocardial Layer of the Injured Heart Modulate Hypertrophic Signaling

Mónica P. A. Ferreira, Sanjeev Ranjan, Sini Kinnunen, Alexandra Correia, Virpi Talman, Ermei Mäkilä, Brianda Barrios‐Lopez, Marianna Kemell, Vimalkumar Balasubramanian, Jarno Salonen, Jouni Hirvonen, Heikki Ruskoaho, Anu J. Airaksinen, Hélder A. Santos

Small· Volume 13· Issue 33
Publisher page

Abstract

Ischemic heart disease is the leading cause of death globally. Severe myocardial ischemia results in a massive loss of myocytes and acute myocardial infarction, the endocardium being the most vulnerable region. At present, current therapeutic lines only ameliorate modestly the quality of life of these patients. Here, an engineered nanocarrier is reported for targeted drug delivery into the endocardial layer of the left ventricle for cardiac repair. Biodegradable porous silicon (PSi) nanoparticles are functionalized with atrial natriuretic peptide (ANP), which is known to be expressed predominantly in the endocardium of the failing heart. The ANP–PSi nanoparticles exhibit improved colloidal stability and enhanced cellular interactions with cardiomyocytes and non‐myocytes with minimal toxicity. After confirmation of good retention of the radioisotope 111‐Indium in relevant physiological buffers over 4 h, in vivo single‐photon emission computed tomography (SPECT/CT) imaging and autoradiography demonstrate increased accumulation of ANP–PSi nanoparticles in the ischemic heart, particularly in the endocardial layer of the left ventricle. Moreover, ANP–PSi nanoparticles loaded with a novel cardioprotective small molecule attenuate hypertrophic signaling in the endocardium, demonstrating cardioprotective potential. These results provide unique insights into the development of nanotherapies targeted to the injured region of the myocardium.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Semiconductor materials and devices · Advancements in Battery Materials · Graphene and Nanomaterials Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Drug Research Program Division of Pharmaceutical Chemistry and Technology Faculty of Pharmacy University of Helsinki Helsinki FI‐00014 Finland

Department of Chemistry University of Helsinki Helsinki FI‐00014 Finland

Division of Pharmacology and Pharmacotherapy Faculty of Pharmacy University of Helsinki Helsinki FI‐00014 Finland

Laboratory of Industrial Physics Department of Physics University of Turku Turku FI‐20014 Finland

Helsinki Institute of Life Science HiLIFE University of Helsinki Helsinki FI‐00014 Finland

Funding

Terveyden Tutkimuksen Toimikunta · Tekes · Academy of Finland · Sigrid Juséliuksen Säätiö · H2020 European Research Council

References (71)

Show source-provided references
1. GBD 2013 Mortality and Causes of Death Collaborators, Lancet · 2015 · 385 · 117
2. World Health Organization The top 10 causes of death http://www.who.int/mediacentre/factsheets/fs310/en/(accessed: December2016).
3. 10.1038/nrm361910.1038/nrm3619 ↗
4. 10.1161/01.CIR.101.25.298110.1161/01.CIR.101.25.2981 ↗
5. 10.1016/S0140-6736(11)60894-510.1016/S0140-6736(11)60894-5 ↗
6. 10.1007/s00441-016-2431-910.1007/s00441-016-2431-9 ↗
7. 10.1016/j.jacc.2013.11.05310.1016/j.jacc.2013.11.053 ↗
8. 10.1016/S0140-6736(11)61038-610.1016/S0140-6736(11)61038-6 ↗
9. 10.1016/S0140-6736(14)61889-410.1016/S0140-6736(14)61889-4 ↗
10. 10.1007/978-3-540-68964-5_1510.1007/978-3-540-68964-5_15 ↗
11. 10.1007/s11897-014-0235-310.1007/s11897-014-0235-3 ↗
12. Ruskoaho H. · Pharmacol. Rev. · 1992 · 44 · 47910.1016/S0031-6997(25)00456-9 ↗
13. 10.1161/01.CIR.80.2.39010.1161/01.CIR.80.2.390 ↗
14. 10.1161/01.HYP.35.1.1910.1161/01.HYP.35.1.19 ↗
15. 10.1161/01.HYP.25.2.22710.1161/01.HYP.25.2.227 ↗
16. 10.1080/0036551015109766510.1080/00365510151097665 ↗
17. 10.1161/01.RES.77.4.75010.1161/01.RES.77.4.750 ↗
18. Mann D. L. · 2001 · 1114
19. 10.1126/scitranslmed.aaf143510.1126/scitranslmed.aaf1435 ↗
20. 10.1016/j.biomaterials.2015.12.02210.1016/j.biomaterials.2015.12.022 ↗
21. 10.1016/j.jconrel.2013.04.02210.1016/j.jconrel.2013.04.022 ↗
22. 10.1093/eurheartj/ehs36610.1093/eurheartj/ehs366 ↗
23. 10.2147/IJN.S2951110.2147/IJN.S29511 ↗
24. 10.1016/0005-2736(95)00248-010.1016/0005-2736(95)00248-0 ↗
25. 10.14797/mdcj-8-1-3610.14797/mdcj-8-1-36 ↗
26. 10.1021/nl202588210.1021/nl2025882 ↗
27. 10.1038/nmat239810.1038/nmat2398 ↗
28. 10.1016/j.biomaterials.2014.05.07810.1016/j.biomaterials.2014.05.078 ↗
29. 10.1021/nn901657w10.1021/nn901657w ↗
30. 10.1146/annurev-med-052914-09192310.1146/annurev-med-052914-091923 ↗
31. 10.1152/physrev.00022.201510.1152/physrev.00022.2015 ↗
32. 10.1038/nprot.2006.17510.1038/nprot.2006.175 ↗
33. 10.1007/s11095-011-0611-610.1007/s11095-011-0611-6 ↗
34. 10.1016/j.biomaterials.2016.03.04610.1016/j.biomaterials.2016.03.046 ↗
35. 10.2217/nnm.11.1910.2217/nnm.11.19 ↗
36. 10.1016/j.ijpharm.2005.10.01010.1016/j.ijpharm.2005.10.010 ↗
37. 10.1021/ja107583h10.1021/ja107583h ↗
38. 10.1038/nbt.333010.1038/nbt.3330 ↗
39. 10.1161/CIRCRESAHA.116.30813910.1161/CIRCRESAHA.116.308139 ↗
40. 10.1161/CIRCRESAHA.115.30777810.1161/CIRCRESAHA.115.307778 ↗
41. 10.1002/smll.20090115810.1002/smll.200901158 ↗
42. 10.1093/toxsci/kfh27810.1093/toxsci/kfh278 ↗
43. Wu D. · J. Visualized Exp. · 2011 · e2899
44. 10.1038/nnano.2011.19110.1038/nnano.2011.191 ↗
45. 10.1074/jbc.270.42.2489110.1074/jbc.270.42.24891 ↗
46. 10.1186/s12929-017-0315-210.1186/s12929-017-0315-2 ↗
47. 10.1074/jbc.M60739120010.1074/jbc.M607391200 ↗
48. 10.1016/j.biomaterials.2015.01.00810.1016/j.biomaterials.2015.01.008 ↗
49. 10.1016/j.biomaterials.2007.12.03310.1016/j.biomaterials.2007.12.033 ↗
50. 10.1097/MOH.0b013e3282f97d8610.1097/MOH.0b013e3282f97d86 ↗
51. 10.1148/radiol.245106159010.1148/radiol.2451061590 ↗
52. M. S. T.Kinnunen M.Välimäki M.Jumppanen G.Boije af Gennäs J.Yli‐Kauhaluoma H.Ruskoaho Patent Application No.: 20165712 2016.
53. 10.1016/j.bbamcr.2006.08.00210.1016/j.bbamcr.2006.08.002 ↗
54. 10.1152/physrev.00054.200910.1152/physrev.00054.2009 ↗
55. 10.1161/CIRCULATIONAHA.106.67958910.1161/CIRCULATIONAHA.106.679589 ↗
56. 10.1172/JCI6283910.1172/JCI62839 ↗
57. 10.1115/1.313851610.1115/1.3138516 ↗
58. 10.1016/0033-0620(87)90016-810.1016/0033-0620(87)90016-8 ↗
59. 10.1152/ajpcell.00037.201010.1152/ajpcell.00037.2010 ↗
60. 10.1016/j.jconrel.2008.06.02410.1016/j.jconrel.2008.06.024 ↗
61. 10.1016/j.biomaterials.2010.12.00810.1016/j.biomaterials.2010.12.008 ↗
62. 10.2147/IJN.S871910.2147/IJN.S8719 ↗
63. 10.1016/j.jacc.2008.11.01410.1016/j.jacc.2008.11.014 ↗
64. 10.1080/1061186060076310310.1080/10611860600763103 ↗
65. 10.1002/cmmi.150110.1002/cmmi.1501 ↗
66. 10.1155/2012/89656210.1155/2012/896562 ↗
67. 10.1002/chem.20070023110.1002/chem.200700231 ↗
68. 10.1074/jbc.M30271920010.1074/jbc.M302719200 ↗
69. 10.1016/0014-4827(70)90333-210.1016/0014-4827(70)90333-2 ↗
70. 10.1211/002235701177543310.1211/0022357011775433 ↗
71. 10.7150/thno.562910.7150/thno.5629 ↗